Survodutide
$925.00
-
Garanzia di consegna Rispedizione gratuita in caso di mancata consegna
-
Purezza ≥99% Produzione diretta dal produttore
-
Certificati di analisi indipendenti Visualizza i COA per questo prodotto →
-
Garanzia di credito negozio Invia qualsiasi risultato COA e ricevi un credito negozio
Prezzi in base al volume
Prezzo per confezione (10 fiale). Lo sconto si applica solo a questo prodotto: non è possibile combinare diversi articoli.
| Quantità | Prezzo | Risparmi |
|---|---|---|
| 1 confezione | $925 | - |
| 2 confezioni | $786 | 15% di sconto |
| 3 confezioni | $668 | 28% di sconto |
| 5 confezioni | $601 | 35% di sconto |
| 10 confezioni | $541 | 42% di sconto |
| 25 confezioni | $487 | 47% di sconto |
Survodutide — Glucagon / GLP-1 Dual Agonist Research Peptide
Survodutide (development code BI 456906) is a once-weekly glucagon receptor and GLP-1 receptor dual agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It is the main research peptide for characterizing paired glucagon + GLP-1 signaling, and is currently in Phase 3 trials (SYNCHRONIZE program) for obesity and MASH (metabolic dysfunction-associated steatohepatitis). It sits in the same “multi-receptor GLP-1” family as tirzepatide and retatrutide but pairs GLP-1 with glucagon specifically, not GIP.
Why Glucagon + GLP-1 Matters
The incretin peptides (semaglutide, tirzepatide) work primarily by amplifying insulin release and slowing gastric emptying. Glucagon receptor signaling is different – it increases hepatic energy expenditure and fat oxidation. Pairing glucagon with GLP-1 in a single molecule combines the caloric-intake side (GLP-1) with the energy-expenditure side (glucagon), which is the mechanistic rationale behind survodutide’s design.
| Receptor | In parole povere, ecco cosa fa |
|---|---|
| GLP-1 receptor | Amplifies insulin release, slows gastric emptying, reduces appetite |
| Glucagon receptor | Increases hepatic energy expenditure and lipid oxidation |
Survodutide vs Tirzepatide vs Retatrutide
Three multi-receptor GLP-1 peptides often get compared in the same research literature, so the distinction matters.
| Composto | Receptors | Developer |
|---|---|---|
| Survodutide | Glucagon + GLP-1 (dual) | Boehringer Ingelheim / Zealand Pharma |
| Tirzepatide | GIP + GLP-1 (dual) | Eli Lilly |
| Retatrutide | GIP + GLP-1 + Glucagon (triple) | Eli Lilly |
All three are once-weekly. Survodutide is unique among them for pairing glucagon with GLP-1 as a two-receptor molecule; retatrutide adds GIP on top of the same pair.
Applicazioni di ricerca
Survodutide is used in studies examining:
- Combined glucagon + GLP-1 signaling in a single molecule
- Hepatic energy expenditure and fat-oxidation endpoints
- MASH (metabolic dysfunction-associated steatohepatitis) models
- Body-composition endpoints vs. GLP-1 monotherapy
- Comparative research vs. tirzepatide and retatrutide
- Dose-response characterization through the published Phase 2 range
Specifiche tecniche
| Formato | Polvere liofilizzata |
| Purezza | ≥99% |
| Alias | BI 456906, glucagon/GLP-1 dual agonist |
| Taglie disponibili | 10 mg |
| Archiviazione | 2-8 °C se non aperto; stabile per oltre 12 mesi |
| Utilizzo | Solo a scopo di ricerca – non destinato all'uso umano |
Ricostituzione
Survodutide arrives as a freeze-dried powder and is reconstituted with bacteriostatic water:
Totale in mg nella fiala ÷ ml di acqua aggiunta = mg per ml
Example: a 10mg vial + 2mL of bacteriostatic water = 5mg per mL.
Una volta ricostituito, conservare a una temperatura compresa tra 2 e 8 °C e utilizzare entro 28-30 giorni.
Note sul protocollo
The following values are reference points extracted from published survodutide Phase 2 trials – not instructions. Published protocols use a stepwise escalation approach across several weeks.
- Starting doses reported in the literature: 0.3mg per administration
- Escalation pattern observed: Bi-weekly steps through 0.9mg, 1.8mg, 2.7mg, up to 4.8mg
- Administration frequency in published trials: Once weekly
- Study durations reported: 46-48 weeks in published Phase 2 trials
Common Questions About Survodutide Research
Is survodutide a GLP-1?
It contains GLP-1 agonism, but it is not a pure GLP-1. Survodutide is a dual agonist – it activates both the glucagon receptor and the GLP-1 receptor. That is what distinguishes it from single-mechanism GLP-1 peptides like semaglutide.
How does survodutide compare to tirzepatide?
They are both once-weekly dual agonists, but they pair GLP-1 with different second receptors. Tirzepatide pairs GLP-1 with GIP (both incretin pathways). Survodutide pairs GLP-1 with glucagon (incretin + energy expenditure). The published endpoints differ as a result.
How does survodutide compare to retatrutide?
Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) and is essentially survodutide’s two receptors plus GIP on top. Head-to-head data does not yet exist in published form; both are in Phase 3.
Is survodutide FDA approved?
No. Survodutide is currently in Phase 3 trials (SYNCHRONIZE program) and is not approved by the FDA for any use. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.
How is survodutide stored?
Le fiale non aperte vanno conservate a una temperatura compresa tra 2 e 8 °C e mantengono la loro stabilità per oltre 12 mesi. Una volta ricostituita con acqua batteriostatica, la soluzione va conservata a una temperatura compresa tra 2 e 8 °C e utilizzata entro 28-30 giorni.
Garanzia di purezza
Ogni lotto ha una purezza pari o superiore al 99%. Inviateci un certificato di analisi (COA) redatto da un ente indipendente e vi accrediteremo un buono acquisto indipendentemente dai risultati riportati.




